Literature DB >> 12153828

Remission in major depressive disorder: a comparison of pharmacotherapy, psychotherapy, and control conditions.

Nicola Casacalenda1, J Christopher Perry, Karl Looper.   

Abstract

OBJECTIVE: The aim of this study was to assess the percentages of full remission in studies of patients with major depressive disorder in which pharmacotherapy, psychotherapy, and control conditions were directly compared.
METHOD: Computerized searches of the MEDLINE and PsychINFO databases up to November 2000 were used to identify six multiple-cell randomized, controlled, double-blind trials for well-defined major depressive disorder in which medications, psychotherapy, and control conditions were directly compared and for which remission percentages were reported.
RESULTS: The studies included a total of 883 outpatients with mild to moderate, primarily nonmelancholic, nonpsychotic major depressive disorder. Treatment duration ranged from 10 to 34 weeks (median=16 weeks). An intent-to-treat analysis indicated that, according to measurements by independent blind raters, antidepressant medication (tricyclic antidepressants and phenelzine) and psychotherapy (primarily cognitive behavior and interpersonal therapies) were more efficacious than control conditions, but there were no differences between active treatments. The percentages of remission for all patients randomly assigned to medication, psychotherapy, and control conditions were 46.4%, 46.3%, and 24.4%, respectively. Furthermore, significantly more patients dropped out of control conditions (54.4%) than either treatment with medication (37.1%) or psychotherapy (22.2%).
CONCLUSIONS: Both antidepressant medication and psychotherapy may be considered first-line treatments for mildly to moderately depressed outpatients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12153828     DOI: 10.1176/appi.ajp.159.8.1354

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  44 in total

1.  Use of depression education materials to improve treatment compliance of primary care patients.

Authors:  Francisca Azocar; Robert B Branstrom
Journal:  J Behav Health Serv Res       Date:  2006-07       Impact factor: 1.505

2.  Comorbid chronic illness and the diagnosis and treatment of depression in safety net primary care settings.

Authors:  Chizobam Ani; Mohsen Bazargan; David Hindman; Douglas Bell; Michael Rodriguez; Richard S Baker
Journal:  J Am Board Fam Med       Date:  2009 Mar-Apr       Impact factor: 2.657

Review 3.  Pharmacogenetics of major depression: insights from level 1 of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial.

Authors:  Magnus Lekman; Silvia Paddock; Francis J McMahon
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

4.  Bouncing back: remission from depression in a 12-year panel study of a representative Canadian community sample.

Authors:  Esme Fuller-Thomson; Marla Battiston; Tahany M Gadalla; Sarah Brennenstuhl
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2014-01-09       Impact factor: 4.328

5.  Oleptro™ (trazodone hydrochloride) extended-release tablets.

Authors: 
Journal:  P T       Date:  2011-02

6.  Characterization of 3(3,4-dihydroxy-phenyl) propionic acid as a novel microbiome-derived epigenetic modifier in attenuation of immune inflammatory response in human monocytes.

Authors:  Jun Wang; Jennifer Blaze; Fatemeh Haghighi; Seunghee Kim-Schulze; Urdvha Raval; Kyle J Trageser; Giulio Maria Pasinetti
Journal:  Mol Immunol       Date:  2020-07-21       Impact factor: 4.407

7.  Interaction effect of brooding rumination and interoceptive awareness on depression and anxiety symptoms.

Authors:  Ryan J Lackner; David M Fresco
Journal:  Behav Res Ther       Date:  2016-08-17

8.  The effect of cognitive behavior therapy-based psychotherapy applied in a forest environment on physiological changes and remission of major depressive disorder.

Authors:  Won Kim; Seoung-Kyeon Lim; Eun-Joo Chung; Jong-Min Woo
Journal:  Psychiatry Investig       Date:  2009-11-17       Impact factor: 2.505

9.  Small Molecule Agonists of Cell Adhesion Molecule L1 Mimic L1 Functions In Vivo.

Authors:  Hardeep Kataria; David Lutz; Harshita Chaudhary; Melitta Schachner; Gabriele Loers
Journal:  Mol Neurobiol       Date:  2015-08-08       Impact factor: 5.590

10.  Depression during pregnancy: views on antidepressant use and information sources of general practitioners and pharmacists.

Authors:  Tessa Ververs; Liset van Dijk; Somaye Yousofi; Fred Schobben; Gerard H A Visser
Journal:  BMC Health Serv Res       Date:  2009-07-17       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.